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Abstract
Osteoporosis, a disorder that affects millions of people worldwide, is characterized by decreased bone mass and microstructural
alterations giving rise to an increased risk of fractures. Osteoporotic fractures can cause acute and chronic nociceptive and
neuropathic pain that mainly affects elderly patients with multiple comorbidities and commonly on different drug regimens.
Central sensitization seems to play a pivotal role in developing and maintaining chronicity of post-fracture pain in
osteoporosis. Antiosteoporosis drugs are able to partially control pain, but additional analgesics are always necessary
for pain due to bone fractures. Nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors reduce
acute pain but with a poor effect on the chronic neuropathic component of pain and with relevant side effects. Opioid drugs
can control the whole spectrum of acute and chronic bone pain, but they differ with respect to their efficacy on neuropathic
components, their tolerability and safety. Chronic pain after osteoporotic fractures requires a multifaceted approach, which
includes a large spectrum of drugs (antiosteoporosis treatment, acetaminophen, NSAIDs, selective COX-2 inhibitors, weak
and strong opioids) and non-pharmacological treatment. Based on a better understanding of the pathogenesis of osteopo-
rotic and post-fracture pain, a guided stepwise approach to post-fracture osteoporotic pain will also better meet the needs
of these patients.
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Key scientific question
& Osteoporosis, a disorder that affects millions of people
worldwide, is characterized by decreased bone mass and
microstructural alterations giving rise to an increased risk
of fractures.
& Osteoporotic fractures can cause acute and chronic
pain that mainly affects elderly patients with multiple
comorbidities and commonly on different drug
regimens.
& The aim of this paper is to summarize the pathogenesis
and systemic treatment of osteoporotic pain.
Key findings
& Osteoporotic fractures induce both acute and chronic no-
ciceptive and neuropathic pain.
& Central sensitization seems to play a pivotal role in devel-
oping and maintaining chronicity of post-fracture pain in
osteoporosis.
& Antiosteoporosis drugs are able to partially control pain,
but additional analgesics are always necessary for pain
due to bone fractures.
& Nonsteroidal anti-inflammatory drugs (NSAIDs) and se-
lective COX-2 inhibitors reduce acute pain but with a poor
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effect on the chronic neuropathic component of pain and
with relevant side effects.
& Opioid drugs can control the whole spectrum of acute and
chronic bone pain, but they differ with respect to their
efficacy on neuropathic components, their tolerability
and safety.
Significance of findings
& Chronic pain after osteoporotic fractures requires a multi-
faceted approach, which includes a large spectrum of
drugs (antiosteoporosis treatment, acetaminophen,
NSAIDs, selective COX-2 inhibitors, weak and strong
opioids) and non-pharmacological treatment.
& Based on a better understanding of the pathogenesis of
osteoporotic and post-fracture pain, a guided stepwise ap-
proach to post-fracture osteoporotic pain will also better
meet the needs of these patients.
Why is the study important and what are
the clinical implications of the findings?
& Bone loss is asymptomatic and progresses without pain
and other symptoms until the occurrence of a fracture.
This event is particularly painful and not sufficiently con-
sidered by clinicians.
& This paper focuses on the pain that characterizes the acute
fracture event.
& This is the first review of such type in the field of osteo-
porosis, opening a window to an increased attention of the
bone doctor towards the pain syndrome.
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